

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 3 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
predefined hit display formats
NEWS 4 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 5 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 6 MAY 30 INPAFAMDB now available on STN for patent family
searching
NEWS 7 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
sequence search option
NEWS 8 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 9 JUN 06 KOREAPAT updated with 41,000 documents
NEWS 10 JUN 13 USPATFULL and USPAT2 updated with 11-character
patent numbers for U.S. applications
NEWS 11 JUN 19 CAS REGISTRY includes selected substances from
web-based collections
NEWS 12 JUN 25 CA/CAPLUS and USPAT databases updated with IPC
reclassification data
NEWS 13 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
patent records
NEWS 14 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
options to display authors and affiliated
organizations
NEWS 15 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 16 JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS 17 JUL 28 CA/CAPLUS patent coverage enhanced
NEWS 18 JUL 28 EPFULL enhanced with additional legal status
information from the epoline Register
NEWS 19 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20 JUL 28 STN Viewer performance improved
NEWS 21 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22 AUG 13 CA/CAPLUS enhanced with printed Chemical Abstracts
page images from 1967-1998
NEWS 23 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 24 AUG 15 CAPLUS currency for Korean patents enhanced
NEWS 25 AUG 25 CA/CAPLUS, CASREACT, and IFI and USPAT databases
enhanced for more flexible patent number searching
NEWS 26 AUG 27 CAS definition of basic patents expanded to ensure
comprehensive access to substance and sequence
information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:46:26 ON 17 SEP 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:46:45 ON 17 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 SEP 2008 HIGHEST RN 1049663-83-3

DICTIONARY FILE UPDATES: 16 SEP 2008 HIGHEST RN 1049663-83-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnoc/properties.html>

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	0.67

FILE 'REGISTRY' ENTERED AT 16:46:57 ON 17 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 SEP 2008 HIGHEST RN 1049663-83-3

DICTIONARY FILE UPDATES: 16 SEP 2008 HIGHEST RN 1049663-83-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10585504.str



chain nodes :

7 8 15 16 17 18 19 20 28

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14 21 22 23 24 25 26

chain bonds :

2-9 3-28 4-7 5-8 6-16 8-15 16-17 16-19 17-18 17-20 18-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 21-22 21-26
22-23 23-24 24-25 25-26

exact/norm bonds :

3-28 4-7 5-8 16-17 16-19 17-18

exact bonds :

1-2 1-6 2-3 2-9 3-4 4-5 5-6 6-16 8-15 17-20 18-21

normalized bonds :

9-10 9-14 10-11 11-12 12-13 13-14 21-22 21-26 22-23 23-24 24-25 25-26

isolated ring systems :

containing 9 : 21 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 28:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 16:47:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 243 TO 877

PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 16:47:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 492 TO ITERATE

100.0% PROCESSED 492 ITERATIONS

106 ANSWERS

SEARCH TIME: 00.00.01

L3 106 SEA SSS FUL L1


=> d scan

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, 2,2,2-trifluoroacetate (1:1)

MF C26 H32 N4 O5 . C2 H F3 O2

CM 1



CM 2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-

MF C19 H14 F3 N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-

MF C20 H18 F N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]-

MF C24 H25 Cl N4 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo-

MF C20 H17 Cl2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN L-Alanine, N-[[[5-[[[1,6-dihydro-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-4-pyrimidinyl]carbonyl]amino]methyl]-2-fluorophenyl]phenoxyphosphinyl]-ethyl ester

MF C31 H32 F N4 O7 P

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, 2,2,2-trifluoroacetate (1:1)

MF C24 H25 F N4 O4 . C2 H F3 O2

CM 1




CM 2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-2-[4-[[[4-(4-fluorophenyl)methyl]amino]methyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-
 MF C27 H24 F2 N4 O3
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-N-[[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-
 MF C20 H13 F6 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-(2,6-
dimethoxyphenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-
ME C22 H22 Cl N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyrimidinecarboxamide, N-((3,4-dichlorophenyl)methyl)-1,6-dihydro-5-
hydroxy-1-methyl-6-oxo-2-phenyl-
MF C19 H15 Cl2 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[2-(dimethylamino)phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-
MF C22 H23 Cl N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]-
MF C25 H27 F N4 O3
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl)methyl]phenyl]-1-methyl-6-oxo-
MF C26 H29 F N4 O4
CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-
 MF C20 H13 F6 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[2-fluoro-6-[methyl(methylsulfonyl)amino]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-
 MF C22 H22 Cl F N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyrimidinecarboxamide, 2-[2-[(dimethylamino)sulfonyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-
 MF C21 H21 F N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 106 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzoic acid, 2-[4-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-
 MF C20 H15 Cl2 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.82	179.49

FILE 'CAPLUS' ENTERED AT 16:48:17 ON 17 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Sep 2008 VOL 149 ISS 12
 FILE LAST UPDATED: 16 Sep 2008 (20080916/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 16:46:26 ON 17 SEP 2008)

FILE 'REGISTRY' ENTERED AT 16:46:45 ON 17 SEP 2008

FILE 'REGISTRY' ENTERED AT 16:46:57 ON 17 SEP 2008

L1	STRUCTURE UPLOADED
L2	7 S L1 SSS SAM
L3	106 S L1 SSS FULL

=> s 13

L4 5 L3

=> d 1-5 ibib abs hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2007:117790 CAPLUS

DOCUMENT NUMBER: 146:184746

TITLE: Preparation of alanine phosphonate derivatives as antiviral agents

INVENTOR(S): Cai, Zhenhong R.; Jabri, Salman Y.; Jin, Haolun; Kim, Choung U.; Metobo, Samuel E.; Mish, Michael R.; Pastor, Richard M.

PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA

SOURCE: PCT Int. Appl., 195pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014352	A2	20070201	WO 2006-US29611	20060727
WO 2007014352	A3	20070329		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006272521	A1	20070201	AU 2006-272521	20060727
CA 2616314	A1	20070201	CA 2006-2616314	20060727
US 20080076740	A1	20080327	US 2006-494818	20060727
EP 1906971	A2	20080409	EP 2006-788911	20060727
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			US 2005-703108P	P 20050727
			WO 2006-US29611	W 20060727

OTHER SOURCE(S): MARPAT 146:184746

GI




AB The invention relates to conjugates comprising a compound that inhibits HIV linked to one or more phosphonate groups, compns., therapeutic methods, and processes and intermediates for preparing them. The conjugates include 2,3-dihydro-1H-pyrrolo[3,4-g]quinolin-1-ones having phosphonylalanine substituents and pharmaceutically-acceptable salts. Thus, compound I was prepared via N-acylation reaction and screened for antiviral activity (EC50 = 1.25 nM).

IT 861674-30-8P 861674-31-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alanine phosphonate derivs. as antiviral agents)


RN 861674-30-8 CAPLUS

CN Phosphonic acid, P-[2-[[[4-[4-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]phenyl]methyl]methylamino]ethyl]-, diethyl ester (CA INDEX NAME)



RN 861674-31-9 CAPLUS

CN Phosphonic acid, P-[2-[[[4-[4-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]phenyl]methyl]methylamino]ethyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:696887 CAPLUS

DOCUMENT NUMBER: 143:194107

TITLE: Pyrimidyl phosphonate antiviral compounds and methods of use

INVENTOR(S): Jin, Haolun; Kim, Choung U.

PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA

SOURCE: PCT Int. Appl., 170 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070901	A2	20050804	WO 2005-US815	20050111
WO 2005070901	A3	20060504		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005206511	A1	20050804	AU 2005-206511	20050111
CA 2552584	A1	20050804	CA 2005-2552584	20050111
US 20050282839	A1	20051222	US 2005-33422	20050111
EP 1711476	A2	20061018	EP 2005-705460	20050111
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
CN 1934093	A	20070321	CN 2005-80002260	20050111
BR 2005006786	A	20070522	BR 2005-6786	20050111
JP 2007517900	T	20070705	JP 2006-549524	20050111
MX 2006PA07906	A	20070214	MX 2006-PA7906	20060710
US 20080153783	A1	20080626	US 2008-585504	20080214
PRIORITY APPLN. INFO.:			US 2004-536010P	P 20040112
			WO 2005-US815	W 20050111
OTHER SOURCE(S):		CASREACT 143:194107; MARPAT 143:194107		



I



II


AB Pyrimidine I and pyrimidinone II phosphonate compds. R1 = H, F, Cl, Br, I, OH, OR, NH2, ammonium, alkylamino, dialkylamino, trialkylammonium, carboxy, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkyl sulfone, aryl sulfone, aryl sulfoxide, arylthio, sulfonamide, alkyl sulfoxide, formyl, ester, amido, 5-7 membered ring lactone, nitrile, azido, nitro, C1-18 alkyl, C1-18 substituted alkyl, C2-18 alkenyl, C2-18 substituted alkenyl, C2-18 alkynyl, C2-18 substituted alkynyl, C6-20 aryl, C6-20 substituted aryl, C2-20 heterocycle, and C2-20 substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, etc. R2a, R5 = independently selected from H, carboxy, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkyl sulfone, aryl sulfone, aryl sulfoxide, arylthio, sulfonamide, alkyl sulfoxide, formyl, ester, amido, 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile, azido, nitro, C1-18 alkyl, C1-18 substituted alkyl, C2-18 alkenyl, C2-18 substituted alkenyl, C2-18 alkynyl, C2-18 substituted alkynyl, C6-20 aryl, C6-20 substituted aryl, C2-20 heterocycle, and C2-20 substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, etc.; R2b, R3, R4 = H, OH, OR, amino, ammonium, alkylamino, dialkylamino, trialkylammonium, carboxy, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkyl sulfone, aryl sulfone, aryl sulfoxide, arylthio, sulfonamide, alkyl sulfoxide, formyl, ester, amido, 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile, azido, nitro, C1-18 alkyl, C1-18 substituted alkyl, C2-18 alkenyl, C2-18 substituted alkenyl, C2-18 alkynyl, C2-18 substituted alkynyl, C6-20 aryl, C6-20 substituted aryl, C2-20 heterocycle, and C2-20 substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, etc.; and methods for viral inhibition are disclosed. The compds. include at least one phosphonate group covalently attached at any site.

IT 861674-34-2
 RL: BCP (Biochemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (preparation of pyrimidyl phosphonate antiviral compds. and methods of use)

RN 861674-34-2 CAPLUS

CN L-Alanine, N-[[5-[[[1,6-dihydro-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-4-pyrimidinyl]carbonyl]amino]methyl]-2-fluorophenyl]phenoxyphosphinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 861674-31-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinyl phosphonate antiviral compds. and methods of use)

RN 861674-31-9 CAPLUS

CN Phosphonic acid, P-[2-[[[4-[4-[[[(4-fluorophenyl)methylamino]carbonyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]phenyl)methyl]methylamino]ethyl]- (CA INDEX NAME)




IT 861674-30-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinyl phosphonate antiviral compds. and methods of use)

RN 861674-30-8 CAPLUS

CN Phosphonic acid, P-[2-[[[4-[4-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]phenyl)methyl]methylamino]ethyl]-, diethyl ester (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:964994 CAPLUS

DOCUMENT NUMBER: 141:410945

TITLE: Preparation of benzyl pyrimidinecarboxamide derivative as HIV integrase inhibitors

INVENTOR(S): Naidu, B. Narasimulu; Walker, Michael A.; Sorenson, Margaret E.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096128	A2	20041111	WO 2004-US11759	20040416
WO 2004096128	A3	20050310		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040229892	A1	20041118	US 2004-824917	20040415
US 7037908	B2	20060502		

PRIORITY APPLN. INFO.: US 2003-465176P P 20030424

OTHER SOURCE(S): MARPAT 141:410945

GI



AB Title compds. represented by the formula I and II [wherein A = methylene or 1,1-disubstituted ethylene; R1 = (un)substituted Ph, pyridinyl, dioxolanylphenyl; R2 = H, Me, OH, oxyalkyl; R5 = (un)substituted Ph or heteroaryl; R6 = alkyl; and pharmaceutically acceptable salts or solvates thereof] were prepared as HIV integrase inhibitors. For example, III was given in a multi-step synthesis starting from 2,6-difluorobenzonitrile. The prepared compds. were tested for HIV-integrase inhibition activity with IC50 values of 0.002-2 μ M. Thus, title compound and their pharmaceutical compns. are useful as HIV integrase inhibitors for the treatment of AIDS or ARC.


IT 518047-27-3P 745803-17-2P 791069-55-1P
 791069-57-3P 791069-59-5P 791069-61-9P
 791069-62-0P 791069-63-1P 791069-64-2P
 791069-65-3P 791069-66-4P 791069-67-5P
 791069-68-6P 791069-70-0P 791069-71-1P
 791069-72-2P 791069-73-3P 791069-76-6P
 791069-91-5P 791069-92-6P 791069-93-7P
 791069-94-8P 791069-95-9P 791069-96-0P
 791069-97-1P 791069-98-2P 791069-99-3P
 791070-00-3P 791070-01-4P 791070-02-5P
 791070-03-6P 791070-04-7P 791070-05-8P
 791070-06-9P 791070-07-0P 791070-08-1P
 791070-09-2P 791070-11-6P 791070-13-8P
 791070-15-0P 791070-16-1P 791070-17-2P
 791070-18-3P 791070-19-4P 791070-20-7P
 791070-21-8P 791070-34-3P 791070-35-4P
 791070-37-6P 791070-39-8P 791070-41-2P
 791070-43-4P 791070-45-6P 791070-47-8P
 791070-49-0P 791070-51-4P 791070-52-5P
 791070-53-6P 791070-54-7P 791070-55-8P
 791070-56-9P 791070-58-1P 791070-59-2P
 791070-63-8P 791070-85-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzyl (aryl)pyrimidinecarboxamide derivative as HIV integrase inhibitors)


RN 518047-27-3 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo- (CA INDEX NAME)




RN 745803-17-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-phenyl- (CA INDEX NAME)




RN 791069-55-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-57-3 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-59-5 CAPLUS
 CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-N-[(3,4-difluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-61-9 CAPLUS
 CN 4-Pyrimidinecarboxamide, N-[(4-chlorophenyl)methyl]-2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-62-0 CAPLUS
 CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-N-[(4-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 791069-63-1 CAPLUS
 CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



RN 791069-64-2 CAPLUS
 CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-65-3 CAPLUS
 CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-N-[(2,4-difluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-66-4 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-N-[(2-methylphenyl)methyl]-6-oxo- (CA INDEX NAME)




RN 791069-67-5 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-68-6 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 791069-70-0 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-N-(1-phenylethyl)- (CA INDEX NAME)




RN 791069-71-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-N-[[2-(methylthio)phenyl]methyl]-6-oxo- (CA INDEX NAME)




RN 791069-72-2 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,6-difluorophenyl)-N-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-73-3 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-76-6 CAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-phenyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 791069-91-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-92-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-93-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-94-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-95-9 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-fluoro-2-(methylsulfonyl)phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



RN 791069-96-0 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-2-[4-fluoro-2-(methylsulfonyl)phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



RN 791069-97-1 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-2-[4-fluoro-2-(methylsulfonyl)phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)

NAME)




RN 791069-98-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[4-fluoro-2-(methylsulfonyl)phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791069-99-3 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2-fluoro-6-[methyl(methylsulfonyl)amino]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-00-3 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-2-[2-fluoro-6-[methyl(methylsulfonyl)amino]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-
(CA INDEX NAME)




RN 791070-01-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[2-fluoro-6-[methyl(methylsulfonyl)amino]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-
(CA INDEX NAME)



RN 791070-02-5 CAPLUS


CN 4-Pyrimidinecarboxamide, 2-(2,6-dimethoxyphenyl)-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



RN 791070-03-6 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-2-(2,6-

dimethoxyphenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-04-7 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-(2,6-dimethoxyphenyl)-N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-05-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-(2,6-dimethoxyphenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-06-9 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]- (CA INDEX NAME)




RN 791070-07-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]- (CA INDEX NAME)




RN 791070-08-1 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]- (CA INDEX NAME)



RN 791070-09-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]- (CA INDEX NAME)




RN 791070-11-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[2-(4-morpholinyl)phenyl]-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 791070-10-5

CMF C23 H23 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 791070-13-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[2-(4-morpholinyl)phenyl]-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 791070-12-7

CMF C23 H22 Cl2 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 791070-15-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[2-(4-morpholinyl)phenyl]-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 791070-14-9

CMF C25 H28 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 791070-16-1 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[2-(4-morpholinyl)phenyl]-6-oxo- (CA INDEX NAME)




RN 791070-17-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[2-(4-morpholinyl)phenyl]-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 791070-16-1

CMF C24 H25 Cl N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 791070-18-3 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2-[(dimethylamino)sulfonyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-19-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-2-[2-[(dimethylamino)sulfonyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-20-7 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2-[(dimethylamino)sulfonyl]phenyl]-N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-21-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[2-[(dimethylamino)sulfonyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-34-3 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-phenyl- (CA INDEX NAME)




RN 791070-35-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-phenyl- (CA INDEX NAME)




RN 791070-37-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-phenyl- (CA INDEX NAME)




RN 791070-39-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-41-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-43-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-(3-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-45-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(4-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-47-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[(4-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-49-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-2-[(4-methoxyphenyl)-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-51-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[2-[(2-hydroxyethyl)amino]phenyl]-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-52-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[2-[(2-hydroxyethyl)amino]phenyl]-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-53-6 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2-[bis(2-hydroxyethyl)amino]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-54-7 CAPLUS

CN Benzoic acid, 2-[4-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]- (CA INDEX NAME)




RN 791070-55-8 CAPLUS

CN Benzoic acid, 2-[4-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]- (CA INDEX NAME)




RN 791070-56-9 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2-(dimethylamino)phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-58-1 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-2-[2-(dimethylamino)phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 791070-59-2 CAPLUS
 CN 4-Pyrimidinecarboxamide, 2-[2-(dimethylamino)phenyl]-N-[(3,4-dimethylphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



RN 791070-63-8 CAPLUS
 CN 4-Pyrimidinecarboxamide, N-[(3-chloro-4-methylphenyl)methyl]-2-[2-(dimethylamino)phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



RN 791070-85-4 CAPLUS
 CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-[(methylamino)carbonyl]phenyl]-6-oxo- (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:716288 CAPLUS

DOCUMENT NUMBER: 141:218924

TITLE: Antiviral agents containing nitrogen-containing heteroaromatic compounds

INVENTOR(S): Fuji, Masahiro; Matsushita, Shihaku; Mikamiyama, Hidenori

PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 54 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004244320	A	20040902	JP 2003-32772	20030210
PRIORITY APPLN. INFO.:			JP 2003-32772	20030210
OTHER SOURCE(S):	MARPAT 141:218924			

GI



I



II


AB The invention provides antiviral agents having HIV integrase inhibitory effects, characterized by containing I [G1 = (substituted) N,; G2 = (substituted) C; G3 = (substituted)N, C, O, S; R1 = (substituted) aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycle; V1, V3 = (substituted) alkylene, alkenylene; V2 = (substituted) alkylene, alkenylene, etc.; X = O, S, NH; Y = hydroxy, mercapto, amino; Z = O, S, NH]. A compound II was prepared, and in vitro tested for its HIV integrase inhibitory effect. A capsule containing an active component 250 mg/capsule was also formulated.

IT 518047-27-3P 745803-17-2P 745803-21-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiviral agents having HIV integrase inhibitory effects containing nitrogen-containing heteroarom. compds.)


RN 518047-27-3 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo- (CA INDEX NAME)




RN 745803-17-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-phenyl- (CA INDEX NAME)



RN 745803-21-8 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2003:334912 CAPLUS

DOCUMENT NUMBER: 138:354001

TITLE: Preparation of N-substituted hydroxypyrimidinone

carboxamide inhibitors of HIV integrase
 Crescenzi, Benedetta; Gardelli, Cristina; Muraglia,
 Ester; Nizi, Emanuela; Orvieto, Federica; Pace, Paola;
 Pescatore, Giovanna; Petrocchi, Alessia; Poma, Marco;
 Rowley, Michael; Scarpelli, Rita; Summa, Vincenzo

PATENT ASSIGNEE(S): Istituto Di Ricerche Di Biologia Molecolare P.

ANGELETTI SPA, ITALY
 PCT Int. Appl., 217 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035077	A1	20030501	WO 2002-GB4753	20021021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463976	A1	20030501	CA 2002-2463976	20021021
CA 2463976	C	20070213		
AU 2002334207	A1	20030506	AU 2002-334207	20021021
AU 2002334207	A2	20030506		
AU 2002334207	B2	20060223		
EP 1441735	A1	20040804	EP 2002-801950	20021021
EP 1441735	B1	20060222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013522	A	20040908	BR 2002-13522	20021021
HU 2004001740	A2	20041228	HU 2004-1740	20021021
JP 2005511543	T	20050428	JP 2003-537644	20021021
JP 3927175	B2	20070606		
CN 1700918	A	20051123	CN 2002-825765	20021021
NZ 533057	A	20051125	NZ 2002-533057	20021021

AT 318140	T	20060315	AT 2002-801950	20021021
PT 1441735	T	20060630	PT 2002-801950	20021021
ES 2258668	T3	20060901	ES 2002-801950	20021021
ZA 2004002796	A	20050120	ZA 2004-2796	20040413
US 20050025774	A1	20050203	US 2004-493280	20040420
US 7169780	B2	20070130		
MX 2004PA03932	A	20040618	MX 2004-PA3932	20040423
IN 2004CN00868	A	20060113	IN 2004-CN868	20040423
NO 2004002165	A	20040525	NO 2004-2165	20040525
NO 325206	B1	20080225		
US 20060258860	A1	20061116	US 2006-491815	20060724
US 7217713	B2	20070515		
US 20070123524	A1	20070531	US 2006-641508	20061219
PRIORITY APPLN. INFO.:			US 2001-339568P	P 20011026
			US 2002-362191P	P 20020306
			WO 2002-GB4753	W 20021021
			US 2004-493280	A3 20040420

OTHER SOURCE(S): MARPAT 138:354001


GI




AB Title compds. I [R1 = H, alkyl, etc.; R2 = alkyl; R3 = H, alkyl; R4 = H, alkyl, alkynyl, etc.] are prepared For instance, 5-[(2,2-dimethylpropanoyl)oxy]-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxylate (general procedures provided for preparation) is reacted with 4-fluorobenzylamine (DMF, 90°, 2 h) to yield II. I are inhibitors of HIV integrase and inhibitors of HIV replication and are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. I can be employed in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

IT 518047-27-3P, N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
 518047-34-2P, N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-[4-(morpholinyl)methyl]phenyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide
 518048-25-4P, N-(2-Ethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
 518048-26-5P, N-(2,3-Dimethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
 518048-27-6P, N-(2,3-Dimethoxybenzyl)-2-[4-[(dimethylamino)methyl]phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide 518048-28-7P
 518048-29-8P, N-(4-Fluorobenzyl)-2-[4-[(dimethylamino)methyl]phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide 518048-30-1P
 518048-31-2P, N-(2,3-Dimethoxybenzyl)-5-hydroxy-1-methyl-6-oxo-2-[4-(pyrrolidin-1-ylmethyl)phenyl]-1,6-dihydropyrimidine-4-carboxamide
 518048-32-3P 518048-33-4P, N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-[4-(pyrrolidin-1-yl)methyl]phenyl]-1,6-dihydropyrimidine-4-carboxamide 518048-34-5P 518048-35-6P,

N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-[4-
 ((piperidinyl)methyl)phenyl]-1,6-dihydropyrimidine-4-carboxamide
 518048-36-7P 518048-37-8P, N-(2,3-Dimethoxybenzyl)-5-
 hydroxy-1-methyl-2-[4-((morpholinyl)methyl)phenyl]-6-oxo-1,6-
 dihydropyrimidine-4-carboxamide 518048-38-9P
 518048-39-0P 518048-40-3P, N-(4-Fluorobenzyl)-5-hydroxy-
 1-methyl-2-[4-((4-methylpiperazin-1-yl)methyl)phenyl]-6-oxo-1,6-
 dihydropyrimidine-4-carboxamide 518048-41-4P
 518048-42-5P, 2-[4-((Diethylamino)methyl)phenyl]-N-(2,3-
 dimethoxybenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-
 carboxamide 518048-43-6P 518048-44-7P,
 2-[4-((Diethylamino)methyl)phenyl]-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-
 oxo-1,6-dihydropyrimidine-4-carboxamide 518048-45-8P
 518048-54-9P, 1-[2-(Dimethylamino)ethyl]-N-(4-fluorobenzyl)-5-
 hydroxy-2-(2-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
 518048-55-0P 518048-58-3P, 2-[4-((4-Ethylpiperazin-1-
 yl)methyl)phenyl]-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-
 dihydropyrimidine-4-carboxamide 518048-59-4P
 518048-60-7P, N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-[4-((2-
 (pyridin-3-yl)piperidinyl)methyl)phenyl]-1,6-dihydropyrimidine-4-
 carboxamide 518048-61-8P 518048-67-4P,
 (R)-N-(4-Fluorobenzyl)-5-hydroxy-2-[4-[[2-(methoxymethyl)pyrrolidin-1-
 yl]methyl]phenyl]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide
 518048-68-5P 518048-69-6P, (S)-N-(4-Fluorobenzyl)-5-
 hydroxy-2-[4-[[2-(methoxymethyl)pyrrolidin-1-yl]methyl]phenyl]-1-methyl-6-
 oxo-1,6-dihydropyrimidine-4-carboxamide 518048-70-9P
 518048-71-0P, N-(4-Fluorobenzyl)-2-[4-[[4-
 fluorobenzyl)amino]methyl]phenyl]-5-hydroxy-1-methyl-6-oxo-1,6-
 dihydropyrimidine-4-carboxamide 518048-72-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of N-substituted hydroxypyrimidinone carboxamide inhibitors of
 HIV integrase)
 RN 518047-27-3 CAPLUS
 CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-
 1-methyl-2-(4-methylphenyl)-6-oxo- (CA INDEX NAME)




RN 518047-34-2 CAPLUS
 CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-
 1-methyl-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo- (CA INDEX NAME)




RN 518048-25-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2-ethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo- (CA INDEX NAME)




RN 518048-26-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo- (CA INDEX NAME)



RN 518048-27-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-2-[4-[(dimethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 518048-28-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-2-[4-[(dimethylamino)methyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-27-6

CMF C24 H28 N4 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-29-8 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(dimethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 518048-30-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(dimethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-29-8

CMF C22 H23 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-31-2 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)




RN 518048-32-3 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-31-2

CMF C26 H30 N4 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-33-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)



RN 518048-34-5 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-pyrrolidinylmethyl)phenyl]-, 2,2,2-trifluoroacetate

(1:1) (CA INDEX NAME)

CM 1

CRN 518048-33-4

CMF C24 H25 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-35-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]- (CA INDEX NAME)




RN 518048-36-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-(1-piperidinylmethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-35-6

CMF C25 H27 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-37-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo- (CA INDEX NAME)




RN 518048-38-9 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-37-8

CMF C26 H30 N4 O6



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 518048-39-0 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-(4-morpholinylmethyl)phenyl]-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518047-34-2
CMF C24 H25 F N4 O4




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 518048-40-3 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo- (CA INDEX NAME)



RN 518048-41-4 CAPLUS
 CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-40-3
 CMF C25 H28 F N5 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 518048-42-5 CAPLUS
 CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



RN 518048-43-6 CAPLUS
 CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-42-5
CMF C26 H32 N4 O5




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 518048-44-7 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



RN 518048-45-8 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-[4-[(diethylamino)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-44-7
CMF C24 H27 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-54-9 CAPLUS

CN 4-Pyrimidinecarboxamide, 1-[2-(dimethylamino)ethyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo- (CA INDEX NAME)




RN 518048-55-0 CAPLUS

CN 4-Pyrimidinecarboxamide, 1-[2-(dimethylamino)ethyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-(2-methylphenyl)-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-54-9

CMF C23 H25 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-58-3 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)




RN 518048-59-4 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-58-3

CMF C26 H30 F N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-60-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-[[2-(3-pyridinyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 518048-61-8 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[4-[[2-(3-pyridinyl)-1-piperidinyl]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-60-7

CMF C30 H30 F N5 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 518048-67-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]phenyl]-1-methyl-6-oxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 518048-68-5 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]phenyl]-1-methyl-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-67-4

CMF C26 H29 F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 518048-69-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl)methyl]phenyl]-1-methyl-6-oxo- (CA INDEX NAME)]

Absolute stereochemistry.



RN 518048-70-9 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-2-[4-[[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]phenyl]-1-methyl-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-69-6

CMF C26 H29 F N4 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 518048-71-0 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-2-[4-[[[(4-fluorophenyl)methyl]amino]methyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (CA INDEX NAME)



RN 518048-72-1 CAPLUS


CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-2-[4-[[[(4-

fluorophenyl)methyl]amino)methyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 518048-71-0

CMF C27 H24 F2 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
27.73	207.22

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.00	-4.00

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:49:05 ON 17 SEP 2008